Current state of art in decision making
Today, insights from basic research and cell line validation results are used to guide decisions on whether to invest in or terminate an oncology drug program.
Today, insights from basic research and cell line validation results are used to guide decisions on whether to invest in or terminate an oncology drug program.
Gordion’s asset evaluation platform quantifies the probability of success for drug programs before clinical efficacy data become available.
Using patient molecular data to predict the outcome of clinical trials is behind a staggering 90% accuracy of the AI model.
